hero-stemrna-neuro

About REPROCELL

REPROCELL is a contract research organization, providing a unique combination of products and services to power your translational research. With scientists and laboratories on three continents, we have the human fresh tissue and iPSC expertise to better translate your discoveries into therapies.

Among the many companies with a stem cell foundation, REPROCELL is one of the oldest and most diversified. Our unique portfolio includes access to human tissue resources, the capability to develop complex iPSC-derived cells and tissues, custom assays for nearly all stages of drug discovery, and 3D cell culture technologies for tissue modeling and assay support.

Furthermore, REPROCELL is leveraging human tissue assay design experience to develop technologies in precision medicine, such as cancer diagnostics. Combined with our recent clinical partnerships, these resources and know-how have positioned the REPROCELL organization to be a more fully integrated supplier of research, clinical, therapeutic, and diagnostic products and services.

Few companies can claim to have this broad line-up of business activities and capabilities, making REPROCELL a unique partner for providing you with the services and materials you need to navigate the complex world of drug discovery and regenerative medicine.


Our Scientists

We proudly employ over 100 scientists across the USA, UK, and Japan. Every member of our team is recruited for their expertise and interest in stem cells and human tissue research. You can find out a bit more about some of our researchers and their publications below.

REPROCELL-04.06.18_0659

Ejaz Ansari, Laboratory Manager and Study Director
Ejaz Ansari is one of REPROCELL’s resident experts in human fresh tissue research. As a leading authority in Organ bath and Ussing studies, Ejaz is Laboratory Manager at our Center for Predictive Drug Discovery.

11JUN19 Bob_Annand_Headshot.png

Bob Annand, Senior Technical Product Manager
Bob has a PhD in biochemistry and over a decade of experience in drug development. He helped to establish and market several of our stem cell products - including the StemRNA 3rd Gen Reprogramming Kit.

REPROCELL-04.06.18_0594

Graeme Macluskie, Precision Medicine Director
Since 2011, Graeme has been designing and delivering preclinical research projects globally. With more than a decade of experience in the industry, he leads an R&D team responsible for tissue-based assays.


Our Values

  • Quality: It is at the core of all we do. Investments in people and infrastructure drive quality thinking, quality products and services, and quality customer and patient experiences.
  • Innovation: Technical advancement requires that we remain flexible and agile. We are forward-thinking and embody the process of continuous improvement. We are dedicated to cultivating and commercializing cutting-edge research and advanced medical technologies to improve human health.
  • Trust: As skilled experts, we are trusted partners in our customer’s success. We seek to build and maintain their trust through honest effort, communication, and transparency.
  • Value: We add value by providing tools and services that de-risk, enable and accelerate customer research workflows and medical healthcare applications
  • Customer focus: We help solve critical challenges and provide customized results by listening, designing, and implementing solutions to address the unique needs of our clients

The History of REPROCELL

Established in 2003 by preeminent Japanese university researchers, REPROCELL quickly became the leading stem cell research company in Japan. Soon thereafter, REPROCELL products were employed by Professor Shinya Yamanaka during his pioneering research on iPSC technologies at Kyoto University.  We were the first company to offer iPSC-derived human cardiomyocytes, hepatocytes, and neuronal cells for research applications and were listed on the Japan JASDAQ / Growth stock market in 2013.

In recent years,  REPROCELL has expanded through a series of acquisitions. This expansion has created a workflow - including human tissue acquisition (BioServe®), RNA reprogramming (Stemgent®), 3D technologies (Reinnervate®), and drug discovery (Biopta®) - in addition to our core capabilities. These acquisitions have been consolidated to regional offices, and the names converted to daughter brands. In the stem cell and drug discovery “market- space”, no other company has such a broad combination of expertise that can be applied to drug discovery and regenerative medicine. To find out more about REPROCELL's capabilities, download our Corporate Capabilities Guide (PDF).

Timeline

Present - 2021 
May 21: Completion of administration of Stemchymal to all enrolled patients in phase II clinical trial in Japan.
Apr 21: Launch of New Testing Service of Identification for Covid-19 Variants.
Mar 21: Bioserve Biotechnologies India Pvt. Ltd. launches NIPT clinical services in India.
Mar 21: Launch of PCR Testing Service for COVID-19.
Feb 21: Patient registration for phase II clinical trial of regenerative therapeutic Stemchymal®.
2020 - 2011
Jul 20: Launch of Personal iPS Service in Japan
Feb 20:
Phase II clinical trial of regenerative medicine product Stemchymal® - Recruitment of first patient

May 19: Launch of cGMP suite in Kawasaki to Accelerate Development of iPSC-derived Glial Progenitors for treatment of CNS disorders.
Mar 19: REPROCELL join Medicines Discovery Catapult’s Virtual R&D network to accelerate drug development.
Feb 19: Joint venture formed with Fox Chase Cancer Center to begin operations on biosample repositories.

Apr 18: Acquired BioServe Biotechnologies India Pvt. Ltd.
Oct 18: Launch of cutting-edge iPS cell genome editing service utilizing next-generation CRISPR/Cas9 technology: CRISP-SNIPER.

Nov 17: REPROCELL Announces Research Collaboration with Q Therapeutics and Dr Mahendra Rao.
Aug 17: Official opening of the "Centre for Predictive Drug Discovery" laboratories in Glasgow, Scotland.
May 17: Alliance is formed with Fox Chase Medical Center (Philadelphia, U.S.A.) to accelerate biomarker and genetic discovery.

Nov 16: Agreement is signed with Steminent Biopharmaceuticals (Taiwan) for Stemchymal cell therapy technology; REPROCELL Medical business unit is created.
Nov 16: REPROCELL Europe founded with full-trading offices located at the Biopta site in Glasgow, Scotland (U.K.); Dr. David Bunton named CEO.
Aug 16: REPROCELL USA founded with full-trading offices located at the BioServe site in Beltsville, MD (U.S.A.); Dr. Rama Modali named CEO.

Nov 15: Acquired Biopta (Glasgow, Scotland, U.K.)

Oct 14: REPROCELL USA, the Company’s affiliate in the U.S.A., acquired the business of iPS cell business department of Stemgent (U.S.A.), and changed its name to Stemgent.
Sep 14: Acquired BioServe (Beltsville, MD, U.S.A.)
Jul 14: Acquired Reinnervate (County Durham, England, U.K.)
Feb 14: Consignment and entrustment agreement with Japan Blood Products Organization for the clinical laboratory measurement work.
Feb 14: Establishment of RC Partners, Inc., which is the Company’s affiliate to invest in a general partner of the venture capital fund called “Cell Innovation Partners, L.P.” that focuses on the creation of next-generation pharmaceutical and medical businesses.

Nov 13: Launch of custom-made disease model cells in collaboration with Takara Bio, Inc. (Cell products).
Oct 13: Shin-Yokohama District (REPROCELL, Inc) was chosen as the Life Innovation Comprehensive Special Zones for International Competitiveness Development.
Jun 13: Listed on the Osaka Securities Exchange JASDAQ Growth Market.

Dec 12: Establishment of the sales office of REPROCELL USA Inc. in Boston.
Oct 12: Professor Shinya Yamanaka of Kyoto University received the Nobel Prize in Physiology or Medicine.
Aug 12: Establishment of the agreement for sales collaboration concerning human iPS cells model for Alzheimer’s disease with PerkinElmer Japan Co., Ltd.
Jun 12: Launch of human iPSC-derived neuron model cells for Alzheimer’s disease.
May 12: Human iPSC-derived hepatocytes (ReproHepato) launch.

Oct 11: A new version of human iPSC-derived cardiomyocytes (ReproCardio2, frozen) launch.
Apr 11: A new feeder-free culture medium ReproFF2 launched.
Apr 11: REPROCELL USA, Ltd. established.
2010 - 2003 Oct 10: Human iPSC-derived DA neuron (ReproNeuro DA) launch.
Jan 10: The headquarters and laboratory have moved to Yokohama.

Apr 09: Human iPSC-derived cardiomyocytes (ReproCardio) and the assay service using it (QTempo) launch.

Aug 08: Cardiotoxicity testing (QTempo) using monkey ES cell-derived cardiomyocytes launch.

Jul 05: National granted project with Kyoto University and pharmaceutical companies “Drug screening and toxicity technology using human ES cells” (2005 to 2010).
Jun 05: Laboratory installed in Tokyo.
Apr 05: Launch of research reagent business: Primate ES cell medium.

Aug 04: Start commercializing Nanog antibodies (human, mouse).

Jun 03: Joint research agreement with Kyoto University.
May 03: Joint research agreement with Tokyo University.
Feb 03: REPROCELL Inc. Established.

The Future of REPROCELL

Over the last decade, REPROCELL has evolved its global infrastructure, corporate organization, and strategy. By leveraging our knowledge base of stem cell technologies, REPROCELL has planned a future that directly involves the pursuit of regenerative medicine market opportunities. This evolution has compelled us to restructure, modify, and define our future vision. If you are interested in finding out more, the REPROCELL Corporate Profile Guide (PDF) concisely explains our current organization and provides a guideline for corporate development and operations.

MM-REPROCELL-CORPORATE-D001001-A4-cover

Download our Corporate Profile

Find out more about the history, philosophy, and business structure of REPROCELL.

screencapture-resources-reprocell-hubfs-website-resources-brochures-and-flyers-MM-DRUG-DISCOVERY-D002001-USH-pdf-2021-07-06-10_39_32

Download our Company Capabilities Brochure

Find out more about the services and products we offer to better translate your discoveries into therapies.